These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33207306)

  • 1. Generation of a human induced pluripotent stem cell line with Cas9 driven by Tet-on operator via AAVS1 safe harbor gene-editing.
    Ding Y; Wang L; Ji W; Chen Z; Wang D; Chen C; Tong H; Han Z; Niu C; Chu M; Huang J; Guo X
    Stem Cell Res; 2020 Dec; 49():102064. PubMed ID: 33207306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
    Thamodaran V; Rani S; Velayudhan SR
    Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the AAVS1 Site by CRISPR/Cas9 with an Inducible Transgene Cassette for the Neuronal Differentiation of Human Pluripotent Stem Cells.
    Gu J; Rollo B; Sumer H; Cromer B
    Methods Mol Biol; 2022; 2495():99-114. PubMed ID: 35696030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers.
    Hong SG; Yada RC; Choi K; Carpentier A; Liang TJ; Merling RK; Sweeney CL; Malech HL; Jung M; Corat MAF; AlJanahi AA; Lin Y; Liu H; Tunc I; Wang X; Palisoc M; Pittaluga S; Boehm M; Winkler T; Zou J; Dunbar CE
    Mol Ther; 2017 Jan; 25(1):44-53. PubMed ID: 28129126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
    Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of human induced pluripotent stem cell line carrying SCN5AC2204>T Brugada mutation (MUSli009-A-1) introduced by CRISPR/Cas9-mediated genome editing.
    Angsutararux P; Luanpitpong S; Chingsuwanrote P; Supraditaporn K; Waeteekul S; Terbto P; Lorthongpanich C; Laowtammathron C; U-Pratya Y; Issaragrisil S
    Stem Cell Res; 2019 Dec; 41():101618. PubMed ID: 31677524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Transgene Silencing of Myeloid-Specific Promoters in the
    Klatt D; Cheng E; Hoffmann D; Santilli G; Thrasher AJ; Brendel C; Schambach A
    Hum Gene Ther; 2020 Feb; 31(3-4):199-210. PubMed ID: 31773990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of a homozygous ARHGAP11B knockout hiPSC line by CRISPR/Cas9 system.
    Liu Y; Jin Y; Chen T; Wu Y; Peng X; Li W; Wei S; Chen M; Zou Q; Guo S; Xu J; Tang C; Zhou X
    Stem Cell Res; 2022 May; 61():102764. PubMed ID: 35358830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
    Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
    Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted gene therapy in human-induced pluripotent stem cells from a patient with primary hyperoxaluria type 1 using CRISPR/Cas9 technology.
    Estève J; Blouin JM; Lalanne M; Azzi-Martin L; Dubus P; Bidet A; Harambat J; Llanas B; Moranvillier I; Bedel A; Moreau-Gaudry F; Richard E
    Biochem Biophys Res Commun; 2019 Oct; 517(4):677-683. PubMed ID: 31402115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a CAG-EGFP tagged cell line (KSCBi017-A-2) from human induced pluripotent stem cells using CRISPR/Cas9.
    Han HW; Im YS; Kim YO; Kwak S; Cho SJ
    Stem Cell Res; 2024 Mar; 75():103303. PubMed ID: 38211411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a human iPSC cell line expressing inducible Cas9 in the "safe harbor" AAVS1 locus.
    Castaño J; Bueno C; Jiménez-Delgado S; Roca-Ho H; Fraga MF; Fernandez AF; Nakanishi M; Torres-Ruiz R; Rodríguez-Perales S; Menéndez P
    Stem Cell Res; 2017 May; 21():137-140. PubMed ID: 28677529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of RUNX1c-eGFP induced pluripotent stem cell, MUSIi012-A-4, using CRISPR/Cas9.
    Srisook P; Laowtammathron C; Lorthongpanich C; Klaihmon P; Terbto P; Waeteekul S; U-Pratya Y; Issaragrisil S
    Stem Cell Res; 2023 Mar; 67():103035. PubMed ID: 36753833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Tet-Inducible CRISPR Platform for High-Fidelity Editing of Human Pluripotent Stem Cells.
    Jurlina SL; Jones MK; Agarwal D; De La Toba DV; Kambli N; Su F; Martin HM; Anderson R; Wong RM; Seid J; Attaluri SV; Chow M; Wahlin KJ
    Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a ST3GAL3 null mutant induced pluripotent stem cell (iPSC) line (UKWMPi002-A-3) by CRISPR/Cas9 genome editing.
    Diouf D; Vitale MR; Zöller JEM; Pineau AM; Klopocki E; Hamann C; Ziegler GC; Vanmierlo T; Van den Hove D; Lesch KP
    Stem Cell Res; 2023 Mar; 67():103038. PubMed ID: 36746102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of a human induced pluripotent stem cell line JHUi003-A with homozygous mutation for spinocerebellar ataxia type 12 using genome editing.
    Feng H; Li Q; Margolis RL; Li PP
    Stem Cell Res; 2021 May; 53():102346. PubMed ID: 34087983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
    Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
    Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.